<DOC>
	<DOCNO>NCT00880009</DOCNO>
	<brief_summary>This phase 2 study bosutinib administer combination letrozole versus letrozole alone post-menopausal woman breast cancer . This 2-part study . Subjects part 1 receive bosutinib letrozole daily , closely monitor 28 day . The second part proceed subject receive dose determine safe base safety evaluation first part . Eligible subject randomly assign receive either bosutinib daily combine daily letrozole , daily letrozole alone specified period time . Subjects follow survival study drug discontinuation .</brief_summary>
	<brief_title>Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer</brief_title>
	<detailed_description>This study terminate 19 April 2009 due unfavorable risk benefit ratio Bosutinib combination Letrozole include one confirm Hy 's law case . 37.5 % patient treatment relate liver event majority severe event result permanent study treatment discontinuation .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>Surgically sterile postmenopausal woman . Confirmed pathologic diagnosis breast cancer . Locally advanced metastatic , locoregional recurrent breast cancer amenable curative treatment surgery radiotherapy . Documented ER+ and/or PgR+ erbB2 tumor base recently analyze biopsy , document local laboratory . At least 1 radiologically measurable lesion define Response Evaluation Criteria Solid Tumors ( RECIST ) . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Prior letrozole ( except adjuvant setting ) , prior bosutinib , prior Src inhibitor . Prior endocrine treatment locally advance metastatic breast cancer ( one prior adjuvant Aromatase Inhibitor ( AI ) agent/regimen permit ) . More 1 prior chemotherapy regimen locally advance metastatic breast cancer . Adjuvant endocrine therapy &lt; =12 month prior day 1 treatment . Disease refractory ( ie , Progressive disease ( PD ) within 6 month initiation therapy ) previous adjuvant antiestrogen therapy . Bone skin site disease . Extensive visceral disease active Central Nervous System ( CNS ) disease . Any cancer within 5 year screen exception ER+ contralateral breast carcinoma , adequately treated cervical carcinoma situ , adequately treat basal squamous cell carcinoma skin . Major surgery radiotherapy within 14 day treatment day . Inadequate hepatic/renal/bone marrow function . History clinically significant uncontrolled cardiac disease . Serious concurrent illness .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>